Research programme: stem cell delivery therapies - CellCyte Genetics

Drug Profile

Research programme: stem cell delivery therapies - CellCyte Genetics

Alternative Names: CCG-TH30; CCG-TH35; CCG-TK45; CCG-TL35; CCG-TL40

Latest Information Update: 28 Apr 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Department of Veterans Affairs
  • Developer CellCyte Genetics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Kidney disorders; Liver disorders; Lung disorders; Myocardial infarction

Most Recent Events

  • 28 May 2008 CellCyte Genetics signs collaborative agreement with Northwestern University's Feinberg School of Medicine to evaluate CCG-TH30 product in a mouse model of acute myocardial infarction
  • 28 May 2008 Preclinical trials in Myocardial infarction in USA (IV)
  • 11 Sep 2007 Preclinical trials in Kidney disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top